bullish
3SBio Inc (1530 HK): Core Biopharmaceutical Portfolio On A Double-Digit Growth Path
506 Views17 Jun 2022 18:31
Tina has highlighted this Insight as a Top Pick
SUMMARY
- 3SBio Inc (1530 HK)'s core products have dominant market share in their respective therapeutic areas, lending a favorable financial profile to the company to fund its R&D and commercialization efforts.
- Flagship drug, TPIAO remained resilient to the COVID-19 and clocked a revenue CAGR of 32% during 2016–2021. Low penetration of TPIAO’s targeted indications leaves further room for its growth.
- Haircare product Mandi has high market share of 70%+ and clocked 64% y/y revenue growth in 2021. 3SBio aims to launch Mandi foam, which will further sharpen its competitive edge.
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Rising
Tina Banerjee
Global Healthcare Analyst
- 3SBio Inc (1530 HK): Hair Product Acts as the Savior; Marginal Growth of Flagship Drug01 Dec 2022
- 3SBio Inc (1530 HK): Core Biopharmaceutical Portfolio On A Double-Digit Growth Path17 Jun 2022
x